Secular Trends in Incidence, Prevalence, and Survival of Pancreatic Cancer in the United Kingdom: A Population-Based Cohort Study from 2000 to 2021
Romito, M. R.; Tan, E. H.; Golozar, A.; Duarte-Salles, T.; Delmestri, A.; Man, W. Y.; Burn, E.; PRIETO-ALHAMBRA, D.; Guarner-Argente, C.; Newby, D.
Show abstract
BackgroundPancreatic cancer is the seventh leading cause of cancer-related mortality worldwide and the fifth in the United Kingdom (UK), with incidence rates nearly matching mortality. MethodsWe conducted a population-based cohort study using Clinical Practice Research Datalink (CPRD) GOLD and Aurum databases including patients aged 18+ with at least one year of prior data, diagnosed between 2000 and 2021. We estimated incidence, period prevalence, and survival at one, five, and ten years, stratified by age, sex, and calendar year. ResultsA total of 10,116 (GOLD) and 20,127 (Aurum) patients were included (median age 73 years, 50% male). Crude incidence rose from 6.9 per 100,000 person-years in 2000 to 14.2 in 2021. Age-standardized rates were lower towards the end of the study. Period prevalence increased from 0.01% to 0.03% over the same period. Median survival was 0.38 (95% CI 0.36-0.39) years in GOLD and 0.39 (95% CI 0.38-0.40) in Aurum. One-, five-, and ten-year survival were 25.3-26.2%, 6.1-6.6%, and 3.8-4.0%, respectively, with no differences by sex. One-year survival improved from 22.5% (95% CI 20.2-25.1) in 2000-2004 to 28.4% (95% CI 26.5-30.5) in 2015-2019. ConclusionsPancreatic cancer incidence and prevalence are increasing in the UK. Rising incidence may partly reflect population aging. Survival remains poor, with only modest short-term improvements. Small improvements in survival highlight more research is needed to improve earlier diagnosis which will lead to better patient outcomes. KEY MESSAGESO_LIThis study aimed to assess long-term trends in the incidence, prevalence, and survival of pancreatic cancer in the United Kingdom using two large primary care databases. C_LIO_LIWe found that both incidence and prevalence of pancreatic cancer have increased between 2000 and 2021, while survival has remained poor, with only modest short-term improvements. C_LIO_LIThese findings highlight the urgent need for strategies focused on early diagnosis and prevention, particularly considering population aging and the increasing burden of modifiable risk factors. C_LI
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Multi-centre derivation and validation of a colitis-associated colorectal cancer risk prediction web-tool 92%
- Quantifying and mitigating the impact of the COVID-19 pandemic on outcomes in colorectal cancer 91%
- GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma 90%
Similar papers in this journal
- Inequalities in the decline and recovery of pathological cancer diagnoses during the first six months of the COVID-19 pandemic: a population-based study 91%
- Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer * translational results from the AIO-PK0104 phase 3 study 90%
- Diagnostic performance of the faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: a service evaluation in the South West of England 90%
Similar papers in this journal
- Identifying markers of health-seeking behaviour and healthcare access in UK electronic health records 90%
- Metabolic disorders and the risk of head and neck cancer: a protocol for a systematic review and meta-analysis 89%
- Improvements in the incidence and survival of cancer and cardiovascular but not infectious disease have driven recent mortality improvements in Scotland: nationwide cohort study of linked hospital admission and death records 2001-2016 89%
Similar papers in this journal
- Molecular subtyping improves prognostication of Stage 2 colorectal cancer 90%
- The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a New Prognostic Biomarker for Lipid-driven Cancers Holds True in Pancreatic Ductal Adenocarcinoma 89%
- Landscape of Clinical Trials in Cancer Cachexia: Assessment of Trends From 1995-2024 89%
Similar papers in this journal
- Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in type 2 diabetes mellitus: a population-based study 91%
- Associations of the 2018 World Cancer Research Fund/American Institute of Cancer Research (WCRF/AICR) Cancer Prevention Recommendations with Stages of Colorectal Carcinogenesis 91%
- Detecting PI3K and TP53 Pathway Disruptions in Early-Onset Colorectal Cancer Among Hispanic/Latino Patients 87%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.